Dominari (NASDAQ:DOMH) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Dominari (NASDAQ:DOMH) from a sell rating to a hold rating in a research note published on Saturday.

Dominari Stock Down 13.8%

DOMH stock opened at $3.32 on Friday. Dominari has a 52-week low of $2.68 and a 52-week high of $8.40. The stock’s 50 day moving average is $3.07 and its two-hundred day moving average is $3.85. The company has a market capitalization of $75.07 million, a PE ratio of -0.82 and a beta of 0.69.

Dominari Dividend Announcement

The company also recently declared a special dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a $0.31 dividend. The ex-dividend date is Friday, May 15th.

Institutional Investors Weigh In On Dominari

A number of institutional investors have recently made changes to their positions in DOMH. Geode Capital Management LLC increased its holdings in shares of Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after acquiring an additional 1,866 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Dominari in the 2nd quarter valued at approximately $158,000. Vanguard Group Inc. increased its holdings in shares of Dominari by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after acquiring an additional 25,694 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Dominari in the 3rd quarter valued at approximately $771,000. Finally, Millennium Management LLC bought a new stake in shares of Dominari in the 3rd quarter valued at approximately $213,000. 42.48% of the stock is currently owned by institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.